Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariona Parera

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Hepatology (Baltimore, Md.)|March 30, 2007
Genetic and catalytic efficiency structure of an HCV protease quasispeciesSandra Franco, Mariona Parera, Ester Aparicio, et al.
AIDS (London, England)|September 28, 2013
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patientsSandra Franco, Ester Aparicio, Mariona Parera, et al.
BMC Microbiology|June 8, 2024
Gut resistome linked to sexual preference and HIV infectionElisa Rubio Garcia, Maria Casadellà, Mariona Parera, et al.
Journal of Virology|April 8, 2011
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsEster Aparicio, Sandra Franco, Mariona Parera, et al.
Plos One|November 5, 2010
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patientsEster Aparicio, Mariona Parera, Sandra Franco, et al.
Plos One|February 14, 2012
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsMontserrat de Castellarnau, Ester Aparicio, Mariona Parera, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
Etiological Characterization of the Cutaneous Ulcer Syndrome in Papua New Guinea Using Shotgun MetagenomicsMarc Noguera-Julian, Camila González-Beiras, Mariona Parera, et al.
Journal of Molecular Biology|July 30, 2008
Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding regionMónica Kisic, Jesús Mendieta, María C Puertas, et al.
AIDS (London, England)|December 4, 2002
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replicationMiguel A Martínez, Arantxa Gutiérrez, Mercedes Armand-Ugón, et al.
Virology|June 9, 2005
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infectionNatalia Tapia, Guerau Fernàndez, Mariona Parera, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|March 30, 2007
Genetic and catalytic efficiency structure of an HCV protease quasispeciesSandra Franco, Mariona Parera, Ester Aparicio, et al.
AIDS (London, England)|September 28, 2013
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patientsSandra Franco, Ester Aparicio, Mariona Parera, et al.
BMC Microbiology|June 8, 2024
Gut resistome linked to sexual preference and HIV infectionElisa Rubio Garcia, Maria Casadellà, Mariona Parera, et al.
Journal of Virology|April 8, 2011
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsEster Aparicio, Sandra Franco, Mariona Parera, et al.
Plos One|November 5, 2010
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patientsEster Aparicio, Mariona Parera, Sandra Franco, et al.
Plos One|February 14, 2012
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsMontserrat de Castellarnau, Ester Aparicio, Mariona Parera, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
Etiological Characterization of the Cutaneous Ulcer Syndrome in Papua New Guinea Using Shotgun MetagenomicsMarc Noguera-Julian, Camila González-Beiras, Mariona Parera, et al.
Journal of Molecular Biology|July 30, 2008
Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding regionMónica Kisic, Jesús Mendieta, María C Puertas, et al.
AIDS (London, England)|December 4, 2002
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replicationMiguel A Martínez, Arantxa Gutiérrez, Mercedes Armand-Ugón, et al.
Virology|June 9, 2005
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infectionNatalia Tapia, Guerau Fernàndez, Mariona Parera, et al.
Pageof 5